Chemed reports Q3 2026 earnings with double‑digit revenue growth and $62.5 M California franchise acquisition

Chemed Corp posted third‑quarter 2026 revenue of $690.9 million, up 10.6% year‑over‑year, and adjusted diluted EPS of $6.75, a 28.1% increase. The VITAS hospice segment generated $457.4 million in revenue, rising 12.2%, while Roto‑Rooter contributed $233.5 million, up 7.5%. The company reacquired California franchise territories for approximately $62.5 million and said integration will take 12‑18 months, and it expects full‑year EPS to be at or slightly above the prior high‑end guidance.

Analysts note the earnings beat and strong VITAS growth support the outlook for continued EPS upside. The California franchise purchase adds about $30 million‑$35 million of 2027 revenue but modest EBITDA, while the $66 million share repurchase returns cash to shareholders.

  • 1Consolidated revenue was $690.9 million, up 10.6% YoY.
  • 2Adjusted diluted EPS was $6.75, up 28.1% YoY.
  • 3GAAP diluted EPS was $5.45, up 22.2% YoY.
  • 4VITAS segment revenue was $457.4 million, up 12.2% YoY.
  • 5Roto‑Rooter segment revenue was $233.5 million, up 7.5% YoY.
  • 6Chemed reacquired California franchise territories for approximately $62.5 million.

Sources